Resultados:  Caso Estudio de las Heparinas

• “The incremental cost-effectiveness of inpatient low-molecular-weight heparin treatment was $7820 per QALY gained”

• “Treatment with low-molecular-weight heparin was cost saving when as few as 8% of patients were treated at home”

Diapositiva anterior

Diapositiva siguiente

Ir a la primera diapositiva

Ver versión gráfica

El estudio de las heparinas indica que “the incremental cost-effectiveness of inpatient low-molecular-weight heparin treatment ($7820 per QALY gained).

El estudio tambien indica que “the treatment with low-molecular-weight heparin was cost saving when as few as 8% of patients were treated at home.”